Skip to main content

Volume 10 Supplement 1

Co-stimulation blockade: from bench to bedside


Edited by Jörg J Goronzy

Publication of this supplement has been sponsored by Bristol-Myers Squibb Company

  1. Over the past decade and a half, advances in our understanding of the pathogenesis of immune-mediated diseases such as rheumatoid arthritis (RA) have translated directly into benefit for patients. Much of this...

    Authors: Andrew P Cope
    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S1
  2. T-cell activation and differentiation depend on the signal strength received by the T-cell receptor and on signals provided by co-stimulatory molecules. The most prominent co-stimulatory molecule is CD28, whic...

    Authors: Jörg J Goronzy and Cornelia M Weyand
    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S3
  3. Currently available information from clinical trials and open-label extensions suggest that abatacept is a good alternative to other biologicals in rheumatoid arthritis. Although at first glance the efficacy o...

    Authors: Rene Westhovens and Patrick Verschueren
    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S4
  4. T-cell biology has regained importance in the pathogenesis of rheumatoid arthritis. Despite the significant improvements associated with the introduction of tumor necrosis factor-α blockade, reasonable proport...

    Authors: Maya H Buch, Edward M Vital and Paul Emery
    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S5

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    111 days submission to accept (Median)

    2023 Usage 
    1,885 Altmetric mentions